Biogen
Top View
- Inebilizumab Reduces Worsening of Disability in Neuromyelitis Optica Spectrum Disorder: Outcomes from the N-Momentum Randomized
- 2019 Annual Report
- Biogen and Gilead Top Tables with Most Valuable R&D Assets
- Earnings Press Release
- View Presentation
- Biopharma Boom Fosters Deal Spree
- Biogen Appealed
- ADUHELM Investor Webcast
- Biogen Inc. - Climate Change 2020
- Regeneron Pharmaceuticals Inc
- Retina Anti-VEGF Biosimilars: How to Prepare for the Coming Wave
- 2015 Medicines in Development for Neurological Disorders a Report on Disorders of the Brain, Spinal Cord and Nerves
- List of Participants
- Biogen Inc. - Climate Change 2019
- COVID-19 Mrna Vaccines (Pfizer-Biontech and Moderna) in Patients with Multiple Sclerosis: a Statement by a Working Group Convene
- Biogen Idec's Agenda
- Biogen-Idec: Growing a Customer-Focused Supply Chain
- Amgen V. Sanofi